Rhythm Pharmaceuticals Expects Higher Product Revenue For Full-year

(RTTNews) - Rhythm Pharmaceuticals, Inc. (RYTM) Friday said it expects full-year product revenue of about $130 million, higher than $77.4 million reported in the previous year.

For the fourth quarter, the company sees revenues from sales of IMCIVREE (setmelanotide) to be approximately $42 million, 26 percent higher than the previous quarter.

The company also added that it is on track to report topline data from the pivotal Phase 3 trial evaluating setmelanotide in acquired Hypothalamic Obesity (HO) in the first half of 2025.

The company plans to report its fourth quarter results in late February.